ClinicalTrials.gg
Enrolling by invitationNCT05396105RAPIDe-2Updated Jul 21, 2026

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

A Phase 2/3 interventional study of deucrictibant and deucrictibant in Hereditary Angioedema, Hereditary Angioedema Type I and Hereditary Angioedema Type II, sponsored by Pharvaris Netherlands B.V.. Enrolling by invitation at 60 sites in 24 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Pharvaris Netherlands B.V. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies in Angioedemas, Hereditary with a site in United States — 12 open to participants now, 18 under way, 10 of them phase 3. Angioedemas, Hereditary · United States.

Planned enrollment
8th of 74
150 · median 57
Started
2022
with 7 others
Phase 2/3
4 of 84
1 open now
Primary completion
2027-06
later than 5 of 17 live
Registered
55th of 84
by date
Lead sponsor
7 of 84
Pharvaris Netherlands B.V.

Among the 84 studies in Angioedemas, Hereditary with a site in United States, this one is the 8th largest by planned enrollment of the 74 interventional ones that give a count, is one of 8 that started in 2022, is one of 4 in phase 2/3, reaches primary completion later than 5 of the 17 other live ones, and was the 55th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

12 of the 84 studies in Angioedemas, Hereditary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Angioedemas, Hereditary with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the safety and efficacy of long-term on-demand treatment with orally administered deucrictibant for acute hereditary angioedema (HAE) attacks, including laryngeal attacks. The study will enroll participants from Study PHA022121-C201 (NCT04618211), Study PHA022121-C306 (NCT06343779) and deucrictibant treatment naïve HAE-nC1INH adult participants who elect to participate in this extension study and meet the eligibility requirements.

Read the detailed description

Part A of the study will enroll adult participants from Study PHA022121-C201. The double-blind treatment assignment from Study PHA022121-C201 will be maintained.

Part B is open-label treatment and includes participants rolling over from Part A, participants from Study PHA022121-C201 who did not participate in Part A, participants aged 12 years and older with HAE type I, type II, or HAE-nC1INH rolling over from Study PHA022121-C306, and deucrictibant treatment naïve adult participants with HAE-nC1INH who elect to participate in this extension study and meet the eligibility requirements.

03

Conditions studied

  • Hereditary Angioedema
  • Hereditary Angioedema Type I
  • Hereditary Angioedema Type II
  • Hereditary Angioedema Types I and II
  • Hereditary Angioedema Attack
  • Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
  • Hereditary Angioedema - Type 1
  • Hereditary Angioedema - Type 2
  • Hereditary Angioedema - Type 3
  • C1 Esterase Inhibitor [C1-INH] Deficiency
  • C1 Esterase Inhibitor Deficiency
  • C1 Esterase Inhibitor, Deficiency of
  • C1 Inhibitor Deficiency
  • Hereditary Angioedema Type III
  • Hereditary Angioedema (HAE)
  • Hereditary Angioedema Type I and II
  • HAE With Normal C1 Esterase Inhibitor

Keywords

  • HAE
  • HAE Type I
  • HAE Type II
  • Oral Treatment
  • Bradykinin B2 Receptor Antagonists
  • On-Demand
  • PHA121
  • PHVS416
  • PHA-022121
  • Deucrictibant
  • HAE Type III
  • HAE-nC1INH
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Provision of the signed form by the participant and/ or legally designated representative. If the participant is a minor (i.e., \<18 years of age or as determined by local law), consent will be obtained from the participant's parent/legally designated representative/guardian and signed assent will be obtained from the participant, per country regulations.
  2. For participants from Study C201, received at least one dose of study drug (including the non-attack visit) in Study C201. For participants from Study C306, participant was randomized (and for adolescent participants ≥12 to \<18 years received a dose of study drug in a non-attack state at Visit 1) and completed Study C306, with 2 attacks treated, or after closure of that study by the Sponsor. Enrollment of adolescents (≥12 to \<18 years or age of adulthood as defined locally) from these studies is with consideration of local age requirements.
  3. Female participants of (or who become of childbearing potential during the study) must agree to the protocol-specified pregnancy testing and to be abstinent from heterosexual intercourse or to use an acceptable method as defined in the protocol and as available locally from enrollment until 30 days after the last study drug administration.
  4. In the opinion of the Investigator, the participant (and parent/caregiver for adolescent participants) is willing and able to comply with the protocol.
  5. Adult participants with HAE type III (HAE-nC1INH) who are deucrictibant-treatment naïve, must meet all of the following:

    i. Recurrent angioedema attacks with diagnostic testing results obtained during screening to confirm C1INH function ≥50% of normal and C4 level not below the lower level of the normal range performed by the central laboratory.

ii. Must either have:

  1. Documented genetic mutation associated with HAE-nC1INH as listed in the Hereditary Angioedema Association (HAEA) and World Allergy Organization (WAO)/European Academy of Allergy and Clinical Immunology (EAACI) Guidelines.

    OR

  2. If no documented mutation: clinical diagnosis with family history of HAE-nC1INH and documented elevations of bradykinin levels in blood. (US, UK and Canada only).

iii. Attacks not responding to treatments with high-dose antihistamine (cetirizine 40 mg/day or equivalent high-dose second-generation antihistamine medication) and no clinical attack symptoms relief if treated with , montelukast, or omalizumab.

iv. Documented effective attack symptom relief with on-demand icatibant treatment.

v. A history of at least 1 HAE attack in the last 3 months prior to Screening

Key Exclusion Criteria:

  1. Any female who is pregnant, plans to become pregnant, or is breast-feeding.
  2. Any other systemic disease (e.g., cardiovascular, gastrointestinal, renal, respiratory, neurological) or significant disease or disorder that, in the opinion of the Investigator, would interfere with the participant's safety or ability to participate in the study.
  3. Use of lanadelumab for long-term HAE prophylactic therapy within 12 weeks prior to enrollment in Part A.
  4. Participants who have recently used short or long-term HAE prophylaxis or on-demand HAE treatment will not be excluded from the study provided the following is observed (i.e., study screening or enrollment/rollover should be delayed allowing for washout):

    i. For Part A:

    1. 2-week washout period before enrollment should be respected for participants who have used any C1-INH product, oral kallikrein inhibitors, attenuated androgens, or anti-fibrinolytics for long-term prophylactic HAE therapy.
    2. 1-week washout period before enrollment should be respected for participants who have used plasma derived C1-INH concentrates (Berinert, Cinryze, Haegarda) for on-demand treatment or short-term prophylaxis.
    3. 24-hour washout period before enrollment should be respected for participants who have used recombinant C1-INH (Ruconest) for on-demand treatment or short-term prophylaxis.

    ii. For Part B:

    a. If a participant is receiving long-term prophylactic therapy with a medication indicated for HAE:, eg, plasma-derived C1INH, danazol at less than or equal to 200 mg/day, antifibrinolytics, berotralstat, or lanadelumab, they must be on a stable dose and regimen for at least 3 months before screening and intends to remain on the same dose for the duration of the study.

  5. History of alcohol or drug abuse within the previous year, or current evidence of substance dependence or abuse
  6. Participation in any other drug study within (except with deucrictibant) currently, within the last 30 days prior to the first deucrictibant dose or within 5 half-lives of study drug at enrollment, whichever is longer.
  7. Discontinued from parent study after enrollment for any study drug-related safety reason or non-compliance including significant protocol deviation.
  8. Use of concomitant medications that are strong inhibitors (e.g., clarithromycin, erythromycin, itraconazole, ketoconazole, ritonavir) or strong CYP3A4 inducers (e.g., carbamazepine and phenytoin).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Part A: Deucrictibant, blinded dose

    Participants will receive the dose of deucrictibant they were randomized to in the PHA022121-C201 study (low, medium, or high dose, each consisting of 3 capsules of deucrictibant or matching placebo) for oral use for on-demand treatment of HAE attacks.

    Drug: deucrictibant

  • Experimental
    Part B: Deucrictibant, open-label

    Participants will receive deucrictibant soft capsules for oral use for on-demand treatment of HAE attacks.

    Drug: deucrictibant

Interventions

  • 3 capsules of deucrictibant or matching placebo will be administered orally for each HAE attack

    Also known as: PHVS416, PHA121, PHA-022121

  • deucrictibant soft capsules will be administered orally for each HAE attack

    Also known as: PHVS416, PHA121, PHA-022121

06

What researchers measure

Primary outcomes

  1. Treatment-emergent Adverse Events (TEAEs), treatment-related TEAEs, treatment-emergent serious adverse events (TESAEs), treatment-related TESAEs, and TEAEs leading to deucrictibant discontinuation

    Time frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).

  2. Heart Rate

    Descriptive in nature, no formal statistical hypothesis testing will be performed.

    Time frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).

  3. Blood pressure

    Systolic and diastolic blood pressure will be measured. Descriptive in nature, no formal statistical hypothesis testing will be performed.

    Time frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).

  4. Body temperature

    Descriptive in nature, no formal statistical hypothesis testing will be performed.

    Time frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).

  5. Clinical laboratory tests

    hematology, blood chemistry, urinalysis

    Time frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).

  6. Electrocardiograms

    Time frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).

  7. Physical Examination

    Time frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).

Secondary outcomes

  1. Time to onset of symptom relief, defined as Patient Global Impression of Change (PGI-C) rating of at least "a little better" for 2 consecutive timepoints within 12 hours post-treatment

    PGI-C evaluates the change in the attack symptoms over time with a 7-point response scale.

    Time frame: Assessed from 1 hour to 12 hours post-treatment

  2. Time to substantial symptom relief, defined as achieving PGI-C rating of at least "better" for 2 consecutive timepoints within 12 hours post-treatment

    PGI-C evaluates the change in the attack symptoms over time with a 7-point response scale.

    Time frame: Assessed from 1 hour to 12 hours post-treatment

  3. Time to substantial symptom relief by Patient Global Impression of Severity (PGI-S), defined as achieving ≥1 point reduction in PGI-S from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment

    PGI-S evaluates the severity of attack symptoms with a 5-point response scale.

    Time frame: Assessed from pre-treatment to 12 hours post-treatment

  4. Proportion of attacks achieving symptom resolution, defined as achieving PGI-S rating of "none" at 24 hours post-treatment.

    Time frame: At 24 hours post-treatment

  5. Proportion of deucrictibant-treated attacks requiring rescue medication within 24 hours post-treatment

    Time frame: Assessed from pre-treatment to 24 hours post-treatment

  6. Time to onset of symptom relief, assessed by a ≥30% reduction in VAS-3/ VAS-5 (Part A) or AMRA (Part B) composite score from the pre-treatment score

    VAS/AMRA scores range between 0 and 100. A larger reduction means a better outcome.

    Time frame: Assessed from pre-treatment to 48 hours post-treatment

  7. Time to substantial symptom relief by VAS-3/ VAS-5 (Part A) or AMRA (Part B), defined as a ≥50% reduction in VAS-3/ VAS-5 (Part A) or AMRA (Part B) composite score from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment

    VAS/AMRA scores range between 0 and 100. A larger reduction means a better outcome.

    Time frame: Assessed from pre-treatment to 12 hours post-treatment

  8. Proportion of study drug-treated attacks reaching almost complete or complete symptom relief by VAS-3/ VAS-5 (Part A) or AMRA (Part B), defined as all item scores in VAS-3/ VAS-5/ AMRA having a value ≤10 at 24 hours post-treatment

    Almost complete or complete symptom relief is defined as all individual item scores in VAS/AMRA having a value ≤10 sustained for 2 consecutive timepoints.

    Time frame: At 24 hours post-treatment

07

Study locations

60 sites
  • Study site
    Birmingham, Alabama 35209, United States
  • Study site
    Little Rock, Arkansas 72205, United States
  • Study site
    San Diego, California 92122, United States
  • Study site
    Santa Monica, California 90404, United States
  • Study site
    Walnut Creek, California 94598, United States
  • Study site
    Colorado Springs, Colorado 80907, United States
  • Study site
    Chevy Chase, Maryland 20815, United States
  • Study site
    Boston, Massachusetts 02115, United States
  • Study site
    Detroit, Michigan 48202, United States
  • Study site
    St Louis, Missouri 63141, United States
  • Study site
    Hershey, Pennsylvania 17033, United States
  • Study site
    Dallas, Texas 75231, United States
  • Study site
    Buenos Aires, B1629AHJ, Argentina
  • Study site
    Salta, 4400, Argentina
  • Study site
    Campbelltown, New South Wales 2560, Australia
  • Study site
    Graz, 8036, Austria
  • Study site
    Vienna, 1090, Austria
  • Study site
    Salvador, Estado de Bahia 41950-640, Brazil
  • Study site
    Ribeirão Preto, 14048-900, Brazil
  • Study site
    Santo André, 09060-870, Brazil
  • Study site
    São Paulo, 05403-000, Brazil
  • Study site
    Sofia, 1431, Bulgaria
  • Study site
    Sofia, 1680, Bulgaria
  • Study site
    Edmonton, Alberta T6G 1Z1, Canada
  • Study site
    Montreal, Quebec, Canada
  • Study site
    Brno, 602 00, Czechia
  • Study site
    Grenoble, 38043, France
  • Study site
    Paris, 75571, France
  • Study site
    Berlin, 12203, Germany
  • Study site
    Frankfurt am Main, 60590, Germany
  • Study site
    Frankfurt am Main, 60596, Germany
  • Study site
    Lübeck, 23538, Germany
  • Study site
    Hong Kong, Hong Kong
  • Study site
    Budapest, 1088, Hungary
  • Study site
    Ashkelon, 78278, Israel
  • Study site
    Catania, 95124, Italy
  • Study site
    Milan, 20097, Italy
  • Study site
    Milan, 20138, Italy
  • Study site
    Naples, 80131, Italy
  • Study site
    Padova, 35128, Italy
  • Study site
    Palermo, 90146, Italy
  • Study site
    Roma, 00133, Italy
  • Study site
    Hiroshima, 730-8518, Japan
  • Study site
    Kanagawa, 216-8511, Japan
  • Study site
    Osaka, 569-8686, Japan
  • Study site
    Tokyo, 113-8431, Japan
  • Study site
    Tokyo, 133-8431, Japan
  • Study site
    Amsterdam, 1005 AZ, Netherlands
  • Study site
    Krakow, 31-503, Poland
  • Study site
    San Juan, 918, Puerto Rico
  • Study site
    San Juan, 927, Puerto Rico
  • Study site
    Cape Town, 7700, South Africa
  • Study site
    Daegu, 41944, South Korea
  • Study site
    Seoul, 03080, South Korea
  • Study site
    Barcelona, 08907, Spain
  • Study site
    Madrid, 28007, Spain
  • Study site
    Lund, 22185, Sweden
  • Study site
    Ankara, 06230, Turkey (Türkiye)
  • Study site
    Istanbul, 34093, Turkey (Türkiye)
  • Study site
    London, E1 2ES, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Jun 2027, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2022
First posted
May 31, 2022
StartActual
Dec 28, 2022
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05396105
Lead sponsor
Pharvaris Netherlands B.V.
Responsible party
Sponsor
First posted
May 31, 2022
Start date
Dec 28, 2022
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Study Director
study director · Pharvaris Netherlands B.V.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucrictibant

Start the discussion